ATE230439T1 - Gezielte gentherapie - Google Patents

Gezielte gentherapie

Info

Publication number
ATE230439T1
ATE230439T1 AT95908333T AT95908333T ATE230439T1 AT E230439 T1 ATE230439 T1 AT E230439T1 AT 95908333 T AT95908333 T AT 95908333T AT 95908333 T AT95908333 T AT 95908333T AT E230439 T1 ATE230439 T1 AT E230439T1
Authority
AT
Austria
Prior art keywords
gene therapy
targeted gene
hypoxia
pro
species
Prior art date
Application number
AT95908333T
Other languages
English (en)
Inventor
Peter John Ratcliffe
John David Firth
Adrian Llewllyn Harris
Christopher William Pugh
Ian James Stratford
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Application granted granted Critical
Publication of ATE230439T1 publication Critical patent/ATE230439T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1217—Phosphotransferases with a carboxyl group as acceptor (2.7.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT95908333T 1994-02-15 1995-02-15 Gezielte gentherapie ATE230439T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9402857A GB9402857D0 (en) 1994-02-15 1994-02-15 Targeting gene therapy
PCT/GB1995/000322 WO1995021927A2 (en) 1994-02-15 1995-02-15 Targeting gene therapy

Publications (1)

Publication Number Publication Date
ATE230439T1 true ATE230439T1 (de) 2003-01-15

Family

ID=10750384

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95908333T ATE230439T1 (de) 1994-02-15 1995-02-15 Gezielte gentherapie

Country Status (9)

Country Link
US (2) US5942434A (de)
EP (2) EP0745131B1 (de)
JP (2) JP3924007B2 (de)
AT (1) ATE230439T1 (de)
DE (1) DE69529276T2 (de)
DK (1) DK0745131T3 (de)
ES (1) ES2185695T3 (de)
GB (1) GB9402857D0 (de)
WO (1) WO1995021927A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9402857D0 (en) * 1994-02-15 1994-04-06 Isis Innovation Targeting gene therapy
DE19617851A1 (de) 1996-05-03 1997-11-13 Hoechst Ag Nukleinsäurekonstrukte mit Genen kodierend für Transportsignale
DE19639103A1 (de) 1996-09-24 1998-03-26 Hoechst Ag Nukleinsäurekonstrukte mit Hybridpromotoren für gentherapeutische Maßnahmen
JP2001501944A (ja) * 1996-10-09 2001-02-13 オックスフォード バイオメディカ（ユーケイ）リミテッド 治療薬のデリバリーにおける単核食細胞
AU770427B2 (en) * 1996-10-09 2004-02-19 Oxford Biomedica (Uk) Limited Mononuclear phagocytes in therapeutic drug delivery
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
IL134897A0 (en) * 1997-09-23 2001-05-20 Oxford Biomedica Ltd Expression of genes in hematopoietic stem cells in ischemic conditions
AU5321299A (en) * 1998-07-28 2000-02-21 Advanced Tissue Sciences, Inc. Genetically engineered cells and tissues
DE69940318D1 (de) * 1998-09-23 2009-03-05 Oxford Biomedica Ltd Polynucleotidkonstrukte und ihre verwendungen
US20040234505A1 (en) * 1998-09-23 2004-11-25 Stuart Naylor Polynucleotide constructs and uses thereof
FR2801319A1 (fr) * 1999-11-18 2001-05-25 Inst Nat Sante Rech Med Construction d'acide nucleique porteuse d'un systeme regulant l'expression d'un gene
US6893867B1 (en) 1999-12-23 2005-05-17 Keith A. Webster Molecular switch for regulating mammalian gene expression
US20040101825A1 (en) * 2001-09-26 2004-05-27 Van Meir Erwin G. Viruses targeted to hypoxic cells and tissues
US7285414B2 (en) * 2000-09-26 2007-10-23 Emory University Viruses targeted to hypoxic cells and tissues
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
US7910549B2 (en) 2001-12-13 2011-03-22 Institute Of Virology Of The Slovak Academy Of Sciences MN gene and protein
GB0202252D0 (en) * 2002-01-31 2002-03-20 Oxford Biomedica Ltd Anemia
WO2003064664A1 (en) * 2002-01-31 2003-08-07 Oxford Biomedica (Uk) Limited Physiologically regulated erythropoietin- exprressing vector for the treatment of anaemia
SI2594265T1 (sl) 2002-11-26 2016-03-31 Institute Of Virology Slovak Academy Of Sciences CA-IX specifični inhibitorji
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US20050048045A1 (en) * 2003-07-02 2005-03-03 Board Of Regents, The University Of Texas System Regulation of urokinase receptor expression by phosphoglycerate kinase
US20060074182A1 (en) * 2004-09-30 2006-04-06 Depuy Products, Inc. Hydrogel composition and methods for making the same
CN101394843A (zh) * 2005-06-06 2009-03-25 菲布罗根公司 使用HIFα稳定剂的改进的贫血治疗
ATE470439T1 (de) * 2005-06-15 2010-06-15 Fibrogen Inc Verwendung von hif 1alfa modulatoren zur behandlung von krebs
CA2642587A1 (en) * 2006-02-16 2007-08-30 Fibrogen, Inc. Compounds and methods for treatment of stroke
EP2005753B1 (de) * 2006-03-30 2016-12-21 LG Electronics, Inc. Verfahren und vorrichtung zum decodieren/codieren eines multi-view videosignals
CN107098970B (zh) 2007-05-03 2021-11-23 新加坡科技研究局 结合细胞内prl-1多肽或prl-3多肽的抗体
US7919006B2 (en) * 2007-10-31 2011-04-05 Freescale Semiconductor, Inc. Method of anti-stiction dimple formation under MEMS
US20100125265A1 (en) * 2008-11-20 2010-05-20 Medtronic Vascular, Inc. Cell Delivery System to Induce Cell Growth and Angiogenesis
EP4519415A2 (de) 2022-05-06 2025-03-12 Antibody Analytics Limited Chemisch induzierte proximitätssysteme

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989008661A1 (en) * 1988-03-18 1989-09-21 The General Hospital Corporation Human heat shock factor
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
EP0650370A4 (de) * 1992-06-08 1995-11-22 Univ California Auf spezifische gewebe abzielende verfahren und zusammensetzungen.
GB9323008D0 (en) * 1993-11-05 1994-01-05 Connors Thomas Improvements relating to cancer therapy
EP0737252A1 (de) * 1993-11-10 1996-10-16 Amgen Inc. Gen - therapie vektor zur behandlung von niedriger oder defektiver herstellung von roten blutzellen
GB9402857D0 (en) * 1994-02-15 1994-04-06 Isis Innovation Targeting gene therapy

Also Published As

Publication number Publication date
DE69529276T2 (de) 2009-09-17
WO1995021927A2 (en) 1995-08-17
EP1136561A3 (de) 2004-03-31
JP3924007B2 (ja) 2007-06-06
EP0745131A1 (de) 1996-12-04
US5942434A (en) 1999-08-24
GB9402857D0 (en) 1994-04-06
US6265390B1 (en) 2001-07-24
DE69529276D1 (de) 2003-02-06
WO1995021927A3 (en) 1995-09-08
ES2185695T3 (es) 2003-05-01
EP1136561A2 (de) 2001-09-26
EP0745131B1 (de) 2003-01-02
JP2006314331A (ja) 2006-11-24
JPH09508531A (ja) 1997-09-02
DK0745131T3 (da) 2003-03-31

Similar Documents

Publication Publication Date Title
ATE230439T1 (de) Gezielte gentherapie
DE69331467D1 (de) Oligonukleotide modulation von protein kinase c
ATE127694T1 (de) Lebende impfstoffe.
BG44877A3 (bg) Метод за експресия на ген,кодиращ човешки имунен интерферон
ATE459715T1 (de) Regulierte gene und ihre verwendungen
ZA9711146B (en) Novel genes coding for amino acid deacetylase with specificity for N-acetyl-L-phosphinotricin, their isolation and use.
DE69433626D1 (de) N-2 substituierte purine
BR9507506A (pt) Processo para exterminar uma célula processo para tratamento de càncer composição e kit terapéutico
SE8800980L (sv) Bindningsinducerande komposition
BR9204191A (pt) Composicao de isca e processo para controlar populacoes de besouro diabroticine,e isca
ATE210466T1 (de) Methoden zur behandlung von atemwegserkrankungen
GR3032457T3 (en) Compositions and methods for modulating rna activity through modification of the 5' cap structure of rna.
AU2001245319A1 (en) Methods of treating diseases with activated protein c
ES8704962A1 (es) Un procedimiento para preparar 1b-d-ribofuranosil, 1-2-4-triazol-3-carboxamida.
DE19681032D2 (de) Gentherapeutisches Nukleinsäurekonstrukt, seine Herstellung und Verwendung zur Behandlung von Herzerkrankungen
HUP9800247A2 (hu) Humán endoglin gén promóter és annak alkalmazása
EP0527941A4 (de)
BR9305489A (pt) Plantas resistentes contra vírus plural e processo para produzir as mesmas
ATE309371T1 (de) Protein mit dnase-aktivität
HK1044568A1 (zh) 一种治疗剂的应激应答性诱导及其使用方法
IT1234390B (it) Prodotti microbici ottenuti mediante la coltivazione do achromobacter stenohalis, per combattere malattie virali
IT8785642A0 (it) Miscela aria ammoniaca. impianto per il trattamento dei sottoprodotti agricoli mediante

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0745131

Country of ref document: EP